Melanotan II vs PT-141 (Bremelanotide)
A side-by-side research comparison of Melanotan II and PT-141 (Bremelanotide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Full name | Melanotan II (MT-II) | Bremelanotide (PT-141 / Vyleesi) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | FDA Approved |
| Mechanism | Non-selective MCR agonist: MC1R produces tanning, MC3R/MC4R increase sexual arousal, MC4R suppresses appetite. Broader receptor activity than PT-141. | MC4R agonist in hypothalamus activating central sexual arousal pathways. Increases dopaminergic signaling independent of vascular mechanisms. |
| Molecular weight | 1,024 Da | 1,025 Da |
| Half-life | 2-3 hours | 2.7 hours |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 0.25-1 mg | 1.75 mg |
| Frequency | Loading: daily/EOD · then 2x weekly maintenance | As needed, ~45 min before activity |
| Route | Subcutaneous injection | Subcutaneous injection |
Melanotan II reported benefits
- Skin tanning
- Enhanced sexual function
- Appetite suppression
- UV protection (melanin)
- Libido enhancement
PT-141 (Bremelanotide) reported benefits
- Increased sexual desire
- Central arousal mechanism
- Works both sexes (research)
- Non-vascular
- Rapid onset
Related comparisons
Research and educational reference only. Not medical advice.